Skip to main content
Premium Trial:

Request an Annual Quote

Genmab Licenses Angiogenesis Targets from Bionomics

NEW YORK, Feb. 14 (GenomeWeb News) - Genmab said today that it has licensed exclusive worldwide rights to develop therapeutics based upon a series of angiogenesis targets identified by Bionomics.

 

Under the agreement, Copenhagen, Denmark-based Genmab has acquired the rights to eight proteins identified and characterized by Bionomics using its Angene angiogenesis platform.

 

Bionomics will receive an upfront fee and additional fees upon the completion of preclinical and clinical milestones, the companies said. Bionomics will also receive milestone payments and royalties on product sales.